Abstract: A conveniently-mounted split side-emitting small panel lamp belongs to the technical field of light-emitting diode (LED) lamps. The conveniently-mounted split side-emitting small panel lamp includes a rear cover; an inner wall of the rear cover is connected to a light source module; reflective paper, a light guide plate, and a diffusion plate are arranged inside the rear cover in sequence from top to bottom; a surface ring is connected below the rear cover, where several clamping blocks are arranged at an edge of the rear cover; the surface ring is provided with clamping slots corresponding to the clamping blocks; a connection terminal is connected above the rear cover; and symmetrically arranged springs are further connected above the rear cover.

Abstract: A split type rotatably removable and conveniently mountable butterfly down lamp includes a mounting seat and a lamp body; a mounting cavity arranged inside the mounting seat; a connecting sheet connected to an inner bottom of the mounting cavity, and the two sides of the connecting sheet of hollow structures; several limiting strips are connected to an inner wall of the mounting cavity; the lamp body includes a shell; a light source module is arranged inside the shell; the light source module includes an aluminum base plate; the aluminum base plate is provided with several lighting LEDs; a reflective cup is arranged above the light source module; a diffusion cover is arranged above the reflective cup; and fastening edges corresponding to the limiting strips are arranged at a circumference of the shell.

Abstract: A conveniently-mounted split side-emitting small panel lamp belongs to the technical field of light-emitting diode (LED) lamps. The conveniently-mounted split side-emitting small panel lamp includes a rear cover; an inner wall of the rear cover is connected to a light source module; reflective paper, a light guide plate, and a diffusion plate are arranged inside the rear cover in sequence from top to bottom; a surface ring is connected below the rear cover, where several clamping blocks are arranged at an edge of the rear cover; the surface ring is provided with clamping slots corresponding to the clamping blocks; a connection terminal is connected above the rear cover; and symmetrically arranged springs are further connected above the rear cover.

Abstract: A media content creation method includes: displaying, by a terminal device, a main modality editing interface; generating, by the terminal device, main modality media content in response to an editing operation performed on the main modality editing interface; converting, by the terminal device, the main modality media content to target sub-modality media content in response to a modality conversion operation; and displaying, by the terminal device, the generated main modality media content and the target sub-modality media content.

Abstract: A lens driving device and a driving method thereof are provided. The lens driving device includes a lens frame, a magnetic group, a driving element group and a control device. The lens frame carries at least one optical element. The magnetic group includes a plurality of pairs of magnetic elements. The driving element group includes at least two coils. The control device supplies power to the driving element group so that the lens frame is driven by the driving element group to move. The driving element group is disposed on the lens frame, and the amount of the lens frame is equal to that of the driving element group. The control device in a first driving state supplies the power to the coils in sequence so that the driving element group is moved from a pair of magnetic elements to another pair of magnetic elements.

Abstract: The present invention provides an oral transmucosal film for delivering agomelatine through the buccal mucosa or sublingual mucosa. The film is a bilayer structure containing a mucoadhesive layer with amorphous agomelatine and a water-soluble backing layer without agomelatine. The film has improved bioavailability and improved palatability. The mucoadhesive layer comprises comprising 0.1%-40% by weight of amorphous agomelatine, or a pharmaceutical acceptable salt thereof, 50-98% by weight of a first film-forming material, 0.5-20% by weight of an oil phase excipient, and 0.5-17% by weight of a surfactant. The backing layer comprises 60-100% (w/w) of one or more film-forming agents.

Abstract: Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Abstract: A method of treating an autoimmune disease such as Sjögren's Syndrome is provided. The method comprises administration of an antibody or an antigen binding portion thereof that specifically binds an epitope of CD40 associated with antagonism. The antibody or the antigen binding portion thereof does not exhibit CD40 agonist activity in either in vitro or in vivo preclinical testing. The antibody inhibits CD40L-induced signaling on DCs, resulting at least in part to reduced production of pro-inflammatory cytokines, and reduction of cell surface activation markers, CD86 and CD54. The antibodies can comprise an Fc region containing a mutation that reduces or eliminates binding to Fc receptors, reducing or eliminating Fc gamma receptor (Fc?R)-mediated cross-linking or clustering.

Abstract: Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Abstract: The application discloses a placement system for a door of a wafer pod, including a loadport. A docking interface is formed in the loadport, a placement mechanism is arranged on one side surface of the loadport, and includes a swing component, a follower component, and a docking plate. The swing component and the follower component are respectively connected to the docking plate, and the swing component can drive the docking plate to place the docking plate obliquely above the docking interface. By utilizing the space at the top of the loadport, the structural layout of the loadport is more reasonable; and the docking plate is placed nearly horizontally after the door is placed at a designated position, and provides a supporting force to the door, so that dependence on the vacuum suction is decreased, thereby avoiding the influences due to fluctuations of air pressure.

Abstract: Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Abstract: The application discloses a placement system for a door of a wafer pod, including a loadport. A docking interface is formed in the loadport, a placement mechanism is arranged on one side surface of the loadport, and includes a swing component, a follower component, and a docking plate. The swing component and the follower component are respectively connected to the docking plate, and the swing component can drive the docking plate to place the docking plate obliquely above the docking interface. By utilizing the space at the top of the loadport, the structural layout of the loadport is more reasonable; and the docking plate is placed nearly horizontally after the door is placed at a designated position, and provides a supporting force to the door, so that dependence on the vacuum suction is decreased, thereby avoiding the influences due to fluctuations of air pressure.

Abstract: Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Abstract: A lens driving device and a driving method thereof are provided. The lens driving device includes a lens frame, a magnetic group, a driving element group and a control device. The lens frame carries at least one optical element. The magnetic group includes a plurality of pairs of magnetic elements. The driving element group includes at least two coils. The control device supplies power to the driving element group so that the lens frame is driven by the driving element group to move. The driving element group is disposed on the lens frame, and the amount of the lens frame is equal to that of the driving element group. The control device in a first driving state supplies the power to the coils in sequence so that the driving element group is moved from a pair of magnetic elements to another pair of magnetic elements.

Abstract: Among others, the present invention provides electric bicycles each including a body frame; a front wheel and a rear wheel; an electric motor configured to provide a mechanical power to at least one of the front and rear wheels; and a battery box configured to removably receive and hold one or more lithium battery packs. The one or more lithium battery packs are configured to power the electric bicycle, and at least one lithium battery pack is capable of being used as a power supply of a separate lithium electric tool.

Abstract: Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Abstract: Among others, the present invention provides electric scooters each including a vertical tube, a handle bar element, a platform configured to support a rider, at least one front wheel and at least one rear wheel, an electric motor configured to provide a mechanical power to at least one of the front and rear wheels, and a battery housing configured to removably receive and hold one or more battery packs. The one or more battery packs are configured to power the electric scooter, and at least one battery pack is capable of being used as a power supply of an electric power or gardening tool.

Abstract: Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.